[Evaluation of cefpiramide in pediatrics]

Area of Science:

• Pharmacology
• Microbiology
• Pediatrics

Context:

• Pediatric infections pose significant health challenges.
• Novel antimicrobial agents are crucial for combating resistant pathogens.
• Cephalosporins are a widely used class of antibiotics.

Purpose:

• To evaluate the efficacy and safety of cefpiramide (CPM) in treating pediatric infections.
• To determine the pharmacokinetic profile of CPM in children.

Summary:

• Cefpiramide (CPM) exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Pseudomonas.
• Pharmacokinetic studies revealed prolonged half-lives for CPM in pediatric patients (4.14-4.76 hours).
• In a clinical trial of 32 pediatric patients, CPM achieved a 90.6% satisfactory clinical response rate for respiratory tract, urinary tract infections, and Staphylococcal Scalded Skin Syndrome (SSSS), with mild, transient side effects observed.

Impact:

• Cefpiramide (CPM) represents a promising therapeutic option for pediatric infections.
• The favorable pharmacokinetic profile and high efficacy suggest CPM could be a valuable addition to the pediatric antibiotic armamentarium.
• Further research may explore CPM's role in managing specific pediatric infectious diseases.